Use of chloroquine, hydroxychloroquine or ivermectin for Covid-19 prevention in vulnerable Brazilian populations

Autores

  • Débora Castanheira Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas
  • Thiago Silva Torres Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas
  • Thais Regis Aranha Universidade Federal da Bahia. Instituto de Saúde Coletiva
  • Fabiane Soares Universidade Federal da Bahia. Instituto de Saúde Coletiva
  • Ines Dourado Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas
  • Valdilea Gonçalves Veloso Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas

DOI:

https://doi.org/10.11606/s1518-8787.2026060006988

Palavras-chave:

Chloroquine, Hydroxychloroquine, Ivermectin, COVID-19, Communication

Resumo

OBJECTIVE: To explore factors associated with the use of chloroquine, hydroxychloroquine, and ivermectin for Covid-19 prevention in socioeconomically vulnerable populations in Brazil. METHODS: A cross-sectional study was conducted using data from the project "Expansion of testing, quarantine, digital health, and telemonitoring strategies to tackle the Covid-19 pandemic in Brazil." Participants were users of 19 primary healthcare units in Salvador (Bahia, BA) and Rio de Janeiro (Rio de Janeiro, RJ) from July 2022 to July 2023. Data were collected via a socioeconomic questionnaire and analyzed using logistic regression to assess factors associated with the use of chloroquine, hydroxychloroquine, or ivermectin for Covid-19 prevention. Multicollinearity was assessed using the generalized variance inflation factor (GVIF), with GVIF^(1/(2*df)) > 5 indicating potential collinearity. Sensitivity analyses were performed using the same backward selection procedure as the main model: excluding “sometimes” responses and stratifying analyses by city (Rio de Janeiro and Salvador). RESULTS: Among 7,505 participants, 11.7% reported using chloroquine, hydroxychloroquine, or ivermectin for Covid-19 prevention. Use was more frequent among people who identified themselves as Brown (ORa = 1.38; 95%CI 1.10–1.75), aged 35–44 (ORa = 1.34; 95%CI 1.03–1.75) or 44–59 (ORa = 1.36; 95%CI 1.06–1.77), evangelical (ORa = 1.32; 95%CI 1.14–1.53), and with comorbidities (ORa = 1.25; 95%CI 1.07–1.47). Having up to two doses of Covid-19 vaccine (ORa = 1.30; 95%CI 1.06–1.59) and being unvaccinated while living with someone with comorbidities (ORa = 10.34; 95%CI 2.27–53.48) also increased the odds of use. GVIF values were low except for city (8.79), due to its interaction with income; the variable was retained for conceptual reasons. Sensitivity analyses yielded results consistent with the main model. CONCLUSION: The use of ineffective medications for Covid-19 prevention was higher among specific demographic groups, reflecting inequalities in access to information and the influence of religious factors. Scientific communication and community engagement strategies remain essential to combat misinformation.

Referências

1. Requejo Domínguez JA, Mino-León D, Wirtz VJ. Quality of clinical evidence and political justifications of ivermectin mass distribution of COVID-19 kits in eight Latin American countries. BMJ Glob Health. 2023;8(5):e010962. https://doi.org/10.1136/bmjgh-2022-010962

2. Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349. https://doi.org/10.1038/s41467-021-22446-z

3. Lalwani P, Salgado BB, Pereira Filho IV, da Silva DSS, de Morais TB do N, Jordão MF, et al. SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study. Int J Infect Dis. 2021;110:141-50. https://doi.org/10.1016/j.ijid.2021.07.017

4. Furlan L, Caramelli B. The regrettable story of the “Covid Kit” and the “Early Treatment of Covid-19” in Brazil. Lancet Reg Health Am. 2021;4. https://doi.org/10.1016/j.lana.2021.100089

5. Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936. https://doi.org/10.1136/bmj.m1936

6. Rossi TRA, Soares CLM, Silva GA, Paim JS, Vieira-da-Silva LM. The response by South Korea to the COVID-19 pandemic: lessons learned and recommendations for policymakers. Cad Saúde Pública. 2022;38(1):e00118621. https://doi.org/10.1590/0102-311x00118621

7. Perlis RH, Lunz Trujillo K, Green J, Safarpour A, Druckman JN, Santillana M, et al. Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19. JAMA Health Forum. 2023;4(9):e233257. https://doi.org/10.1001/jamahealthforum.2023.3257

8. Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28(3):e299-318. https://doi.org/10.1097/mjt.0000000000001377

9. Brito Junior I, Saraiva FA, Bruno NC, Silva RF, Hino CM, Yoshizaki HTY. Inefficacious drugs against covid-19: analysis of sales, tweets, and search engines. Rev Saúde Pública. 2024;58:06. https://doi.org/10.11606/s1518-8787.2024058005413

10. Vidal JE, Hernandez AV, Liu A, Roman YM, Burela PA. Eficácia e segurança de ivermectina para o tratamento de pacientes com covid-19 não hospitalizados: revisão sistemática e meta-análise de 12 estudos clínicos randomizados controlados incluindo 7.035 casos. Braz J Infect Dis. 2023;27(Suppl. 1):102911. https://doi.org/10.1016/j.bjid.2023.102911

11. Ferreira RM, Beranger RW, Sampaio PPN, Mansur Filho J, Lima RAC. Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience. Rev Assoc Med Bras (1992). 2021;67(10):1466-71. https://doi.org/10.1590/1806-9282.20210661

12. Martins-Filho PR, Ferreira LC, Heimfarth L, Araújo AAS, Quintans-Júnior LJ. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am. 2021;2:100062. https://doi.org/10.1016/j.lana.2021.100062

13. Marcolino MS, Meira KC, Guimarães NS, Motta PP, Chagas VS, Kelles SMB, et al. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis. 2022;22(1):639. https://doi.org/10.1186/s12879-022-07589-8

14. Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK, Bitty-Anderson AM, et al. Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. BMC Public Health. 2021;21(1):58. https://doi.org/10.1186/s12889-020-10145-1

15. Pitta MGR, Lima LP, Carvalho JS, Teixeira DRC, Nunes TRS, Moura JAS, et al. Análise do perfil de automedicação em tempos de COVID-19 no Brasil. Res Soc Dev. 2021;10(11):e28101119296. https://doi.org/10.33448/rsd-v10i11.19296

16. Branco LL, Lobato MYF, Borges JFT, Oliveira RCS. Automedicação durante a pandemia de COVID-19 e fatores associados. Res Soc Dev. 2023;12(2):e11212239924. https://doi.org/10.33448/rsd-v12i2.39924

17. Mejia CR, Ruiz-Aquino M, Garcia-Arteta G, Ramos G, Astete-Pérez I, Pineda-Cáceres M, et al. Factors associated with the use of medicines and self-medication during the COVID-19 pandemic in 12 Latin American countries. Heliyon. 2024;10(1):e22299. https://doi.org/10.1016/j.heliyon.2023.e22299

18. Wegbom AI, Edet CK, Raimi O, Fagbamigbe AF, Kiri VA. Self-medication practices and associated factors in the prevention and/or treatment of COVID-19 virus: a population-based survey in Nigeria. Front Public Health. 2021;9. https://doi.org/10.3389/fpubh.2021.606801

19. Salvador-Carrillo J, Campos-Loza L, Guillen-Carbajal D, Osada J, Zevallos A, Torres-Roman JS. Use of ivermectin and factors associated with the prevention and/or treatment of COVID-19: a cross-sectional online survey in the province of Chincha, Peru. F1000Res. 2024;12:149. https://doi.org/10.12688/f1000research.128675.3

20. Silva NBL, Rocha RPS, Andrade ACS, Terças-Trettel ACP, Muraro AP. Prevalência do uso de ivermectina para prevenir COVID-19 durante a pandemia em Mato Grosso: estudo transversal de base domiciliar. Rev Bras Epidemiol. 2023;26:e230026. https://doi.org/10.1590/1980-549720230026.2

21. Magno L, Rossi TRA, Castanheira D, Torres TS, Santos CC, Soares F, et al. Expansion of testing, isolation, quarantine, e-health and telemonitoring strategies in socioeconomically vulnerable neighbourhoods at primary healthcare in the fight against COVID-19 in Brazil: a study protocol of a multisite testing intervention using a mixed method approach. BMJ Open. 2023;13(6):e068016. https://doi.org/10.1136/bmjopen-2022-068016

22. Olukosi AY, Fowora M, Adeneye AK, Chukwu E, Aina O, Ajibaye O, et al. A survey of chloroquine use for prevention and treatment of COVID-19 in Nigeria. Afr Health Sci. 2023;23(1):83-92. https://doi.org/10.4314/ahs.v23i1.10

23. Gaviria-Mendoza A, Mejía-Mazo DA, Duarte-Blandón C, Castrillón-Spitia JD, Machado-Duque ME, Valladales-Restrepo LF, et al. Self-medication and the “infodemic” during mandatory preventive isolation due to the COVID-19 pandemic. Ther Adv Drug Saf. 2022;13:20420986221072376. https://doi.org/10.1177/20420986221072376

24. Quispe-Cañari JF, Fidel-Rosales E, Manrique D, Mascaró-Zan J, Huamán-Castillón KM, Chamorro-Espinoza SE, et al. Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. Saudi Pharm J. 2021;29(1):1-11. https://doi.org/10.1016/j.jsps.2020.12.001

25. Floss M, Tolotti G, Rossetto AS, Camargo TS, Saldiva PHN. Linha do tempo do “tratamento precoce” para Covid-19 no Brasil: desinformação e comunicação do Ministério da Saúde. Interface. 2022;27:e210693. https://doi.org/10.1590/interface.210693

26. Melo JRR, Duarte EC, Moraes MV, Fleck K, Arrais PSD. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cad Saúde Pública. 2021;37(4):e00053221. https://doi.org/10.1590/0102-311X00053221

27. Galvão T, Noll PRES, Silveira EA, Noll M. Fake news and misinformation in Brazil: critical analyses regarding scientific information in pandemic times. J Hum Growth Dev. 2023;33(3):493-500. https://doi.org/10.36311/jhgd.v33.14938

28. Chopra D, Bhandari B, Sidhu JK, Jakhar K, Jamil F, Gupta R. Prevalence of self-reported anxiety and self-medication among upper and middle socioeconomic strata amidst COVID-19 pandemic. J Educ Health Promot. 2021;10:73. https://doi.org/10.4103/jehp.jehp_864_20

29. Makowska M, Boguszewki R, Nowakowski M, Podkowińska M. Self-medication-related behaviors and Poland’s COVID-19 lockdown. Int J Environ Res Public Health. 2020;17(22):8344. https://doi.org/10.3390/ijerph17228344

Downloads

Publicado

2026-04-23

Edição

v. 60 n. S1 (2026)

Seção

Artigos Originais

Licença

Direitos autorais (c) 2026 Débora Castanheira, Thiago Silva Torres, Thais Regis Aranha, Fabiane Soares, Ines Dourado, Valdilea Gonçalves Veloso

Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Como Citar

Castanheira, D., Torres, T. S., Aranha, T. R., Soares, F., Dourado, I., & Veloso, V. G. (2026). Use of chloroquine, hydroxychloroquine or ivermectin for Covid-19 prevention in vulnerable Brazilian populations. Revista De Saúde Pública, 60(S1), e247422. https://doi.org/10.11606/s1518-8787.2026060006988